• Platelet dense granule (DG) deficiency is a major abnormality in RUNX1 haplodeficiency patients.
Summary. Background: Inherited RUNX1 haplodeficiency is associated with thrombocytopenia and platelet dysfunction. Dense granule (DG) deficiency has been reported in patients with RUNX1 haplodeficiency, but the molecular mechanisms are unknown. Platelet mRNA expression profiling in a patient previously reported by us with a RUNX1 mutation and platelet dysfunction showed decreased expression of PLDN (BLOC1S6), which encodes pallidin, a subunit of biogenesis of lysosomerelated organelles complex-1 (BLOC-1) involved in DG biogenesis. PLDN mutations in the pallid mouse and Hermansky-Pudlak syndrome-9 are associated with platelet DG deficiency. Objectives: We postulated that PLDN is a RUNX1 target, and that its decreased expression leads to platelet DG deficiency in RUNX1 haplodeficiency. Results: Platelet pallidin and DG levels were decreased in our patient. This was also observed in two siblings from a different family with a RUNX1 mutation. Chromatin immunoprecipitation and electrophoretic mobility shift assays with phorbol ester-treated human erythroleukemia (HEL) cells showed RUNX1 binding to RUNX1 consensus sites in the PLDN1 5 0 upstream region. In luciferase reporter studies, mutation of RUNX1 sites in the PLDN promoter reduced activity. RUNX1 overexpression enhanced and RUNX1 downregulation decreased PLDN1 promoter activity and protein expression. RUNX1 downregulation resulted in impaired handling of mepacrine and mislocalization of the DG marker CD63 in HEL cells, indicating impaired DG formation, recapitulating findings on PLDN downregulation. Conclusions: These studies provide the first evidence that PLDN is a direct target of RUNX1 and that its dysregulation is a mechanism for platelet DG deficiency associated with RUNX1 haplodeficiency.
Introduction
Mutations in transcription factors, particularly RUNX1, are being recognized more frequently as the genetic basis of platelet dysfunction in patients with bleeding disorders [1] [2] [3] . RUNX1 haplodeficiency is associated with familial thrombocytopenia, impaired platelet function and megakaryopoiesis, and a predisposition to developing acute leukemia [2, 4] . Several platelet abnormalities have been reported in patients with RUNX1 mutations, including impaired aggregation, secretion and protein phosphorylation, and storage pool deficiency (SPD) [2, [5] [6] [7] .
Platelet granule deficiency leading to impaired platelet function is an important abnormality associated with RUNX1 mutations [2, 5] . In 1969, Weiss et al. [8] described a family with inherited platelet dysfunction resulting from reduced platelet ADP and ATP levels, indicating a dense granule (DG) SPD. This affected family, and some of the others described with deficiencies of DGs or a-granules, have been subsequently shown to carry RUNX1 mutations [6, 9, 10] . In studies using targeted high-throughput sequencing, some patients considered to have DG SPD were found to have RUNX1 mutations [11] . Moreover, Connelly et al. [10] differentiated induced pluripotent stem cells from skin fibroblasts of two patients with RUNX1 mutations, and showed abnormalities in megakaryocyte production and structure, including a DG deficiency. Targeted in vitro correction of RUNX1 mutations could reverse the megakaryocyte defects, providing evidence that RUNX1 mutation was the cause. The mechanisms leading to the DG deficiency in patients with RUNX1 mutations are unknown. In general, platelet DG deficiency may arise by multiple mechanisms and be associated with granule abnormalities in other cells (such as melanocytes and neurons), as occurs in HermanskyPudlak syndrome (HPS) [12, 13] .
We have reported detailed studies in a patient with inherited heterozygous RUNX1 mutation, thrombocytopenia, and abnormal platelet function [14, 15] . The platelet abnormalities included impaired agonist-induced aggregation, DG secretion, myosin light chain and pleckstrin phosphorylation, and decreased platelet protein kinase C (PKC)-h levels. Platelet mRNA expression profiling showed downregulation of several genes, including MYL9, PF4, and ALOX12, and we have shown that these are direct transcriptional targets of RUNX1 [2, [16] [17] [18] [19] . In addition, platelet expression of PLDN (pallidin) was downregulated four-fold (fold change of 0.239, P < 0.029) in the patient [20] .
PLDN encodes a 172-amino acid protein [21] and is linked to granule biogenesis. It is mutated in the naturally occurring mouse model of HPS (the pallid mouse) [21] , and is associated with DG deficiency and a pigmentary disorder. More recently, a homozygous PLDN mutation has been reported in a patient with HPS-9 [22] . Pallidin is one of eight subunits that constitute biogenesis of lysosome-related organelles complex-1 (BLOC-1), which plays a major role in granule/vesicle biogenesis [13] . Human PLDN has two known transcripts: PLDN1 is expressed ubiquitously, whereas PLDN2 is expressed in brain, testes, and leukocytes [21] . Because of the association of platelet DG deficiency with PLDN abnormalities [21, 22] , and the DG deficiency observed in patients with RUNX1 mutations [2, 5] , we postulated that PLDN is a direct transcriptional target of RUNX1, and that its decreased expression may constitute a mechanism for the DG defect. Here, we present the first evidence that PLDN is a direct transcriptional target of RUNX1, and that RUNX1 or pallidin downregulation is associated with altered DG biogenesis. These studies provide a mechanism involving pallidin for the DG deficiency associated with human RUNX1 mutations.
Materials and methods

Patient information
We have previously described [14, 15, 20] the clinical presentation and studies in a 33-year-old white male, documenting mild thrombocytopenia with decreased agonist-stimulated platelet aggregation, secretion, glycoprotein (GP) IIb-IIIa activation, and phosphorylation of pleckstrin and myosin light chain; the platelet PKC-h level was also decreased. The patient has a single point mutation in RUNX1, in intron 3 at the splice acceptor site for exon 4, leading to a frameshift and premature termination in the Runt domain [15] .
We report here studies in two additional patients (a male aged 8 years, and a female aged 3 years) with thrombocytopenia and a RUNX1 mutation (c.508 + 1G>1). The maternal grandmother and great uncle had a history of acute myeloid leukemia. The male subject has had abnormal platelet function on laboratory testing.
This research was approved by the institutional human subjects review board, and all participants gave written informed consent.
Materials
The RUNX1 small interfering RNA (siRNA), PLDN siRNA and control siRNA, antibodies against RUNX1, CD63, cappuccino and b-actin and preimmune IgG were from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Antibodies against pallidin were from Abnova (Taipei, Taiwan). Antibodies against snapin were from Proteintech Group (Rosemont, IL, USA). Phorbol 12-myristate 13-acetate (PMA) was from Enzo Life Sciences (Farmingdale, NY, USA). Mepacrine (quinacrine dihydrochloride) was from EMD Millipore Corporation (Temecula, CA, USA). The Luciferase Reporter Assay System kit, PCR reagents, PGL3-basic vector and the Renilla luciferase control vector were from Promega Biotech (Madison, WI, USA). TRIzol reagent was from Invitrogen (Carlsbad, CA, USA). All oligonucleotides and IRDye-labeled probes were synthesized by Integrated DNA Technologies, (Coralville, IA, USA). Fluorophore-conjugated secondary antibodies raised in donkey were from Jackson ImmunoResearch Laboratories (West Grove, PA, USA).
Preparation of platelet RNA and proteins
Whole blood samples (42.5 mL) were collected from the subjects into 7.5 mL each of acid citrate dextrose solution (71.4 mm citric acid, 85 mM sodium citrate-dihydrate, 11.1 mM dextrose), as described previously [20] . The platelet pellet was washed twice in HEPES buffer (pH 6. Table S1 ). As controls, PCR was performed on the genomic DNA from the initial sample and on the solubilized cross-linked chromatin prior to immunoprecipitation (input DNA). PCR products were analyzed by electrophoresis on 1% agarose gels.
Electrophoretic mobility shift assay (EMSA)
Nuclear protein was extracted from PMA (30 nM)-treated HEL cells with NE-PER Nuclear and Cytoplasmic Extraction Reagents (ThermoFisher Scientific). IRDyelabeled oligonucleotides were double-stranded. Ten micrograms of nuclear protein was incubated with 0.2 ng of labeled probe and 1 lg of poly(dI-dC) in a 15-lL reaction, containing 10% glycerol, 20 mM HEPES, 30 mM KCl, 30 mM NaCl, 3 mM MgCl 2 , and 1 mM dithiothreitol, for 10 min at room temperature (~22°C) and for 10 min on ice before analysis on 4% polyacrylamide gels run at 4°C. For supershift assays, 1 lg of anti-RUNX1 antibodies or control IgG was incubated with the nuclear extract for 10 min at room temperature before addition of IRDye-labeled probe. Competition assays were carried out by addition of 200-fold excess unlabeled probe at the stated concentrations in 2 lL of nuclear extract and incubated for 10 min on ice before addition of labeled probe. The oligonucleotide sequences used to prepare DNA probes with the binding sites are shown in Table S2 .
Promoter and plasmid construction
Genomic DNA was isolated from human blood with the Genomic DNA isolation kit (Qiagen, Valencia, VA, USA). The promoter region of PLDN was obtained by PCR amplification of genomic DNA with the primers listed in Table S3 . Promoter luciferase constructs were generated with DNA fragments containing human PLDN promoter regions À 2288 to À 23, and À 105 to À 23 (from ATG), and cloned into the PGL3-basic vector (Promega Biotech). The constructs with RUNX1 sites mutated were generated with the Quick Change SiteDirected system (Stratagene, La Jolla, CA, USA) (Table S3 ).
Luciferase reporter assay HEL cells were grown in 24-well plates and treated with 30 nM PMA. Transfections were performed with Lipofectamine 2000 Reagent (Invitrogen). Cells (2 9 10 5 ) were cotransfected with 200 ng of either the empty PGL3-basic plasmid (Promega Biotech) or PGL3-basic plasmid containing the PLDN promoter region, and 10 ng of pRL-TK vector DNA (Promega Biotech). The pRL-TK vector, which provided constitutive expression of Renilla luciferase, was cotransfected as an internal control. Cells were analyzed at 24 h or 48 h for luciferase activity with the Dual Luciferase Reporter Assay system (Promega Biotech).
Quantitative real-time PCR
Total RNA was extracted with TRIzol Reagent (Invitrogen) and quantified with NanoDrop (Thermo Scientific, Tewksbury, MA, USA). RNA (1 lg) was reverse-transcribed by the use of Superscript III (Applied Biosystems, Grand Island, NY, USA). The resulting cDNA was diluted 1 : 50 in nuclease-free water for real-time PCR reactions. The final concentration of primers in each reaction was 0.1 lM. The PCR parameters were: 95°C for 10 min, and 40 cycles of 95°C for 15 s, 55°C for 20 s, and 72°C for 20 s. PCR was performed with a Master Cycler Real-Time PCR System (Eppendorf, Hauppauge, NY, USA), and relative abundances were calculated by the DDC T method, with the glyceraldehyde-3-phosphate dehydrogenase gene as the reference gene. The forward (F) and reverse (R) primers used are shown in Table S4 .
Cell extracts and immunoblotting
Cell extracts lysed with M-Per Protein Extraction Reagent (Pierce, Grand Island, NY, USA) with protease inhibitors (Enzo Life Sciences were subjected to 10% or 12% SDS-PAGE, transferred to poly(vinylidene difluoride) membranes (Millipore, Billerica, MA, USA), and probed with the indicated antibodies. Proteins were detected with IRDye-labeled secondary antibodies and the Odyssey Infrared Imaging system (Li-Cor Biosciences, Lincoln, NE, USA). The quantification from the immunoblots was performed with IMAGEJ software. 
RUNX1 overexpression
The expression plasmid RUNX1-pCMV6-XL4 and empty pCMV6-XL4 vector were obtained from OriGene Technologies (Rockville, MD, USA). HEL cells were cotransfected by the use of Lipofectamine 2000 (Invitrogen) with 1.25 lg of plasmid RUNX1-pCMV6-XL4 or empty vector and PLDN promoter luciferase reporter constructs (-2288/PGL3-basic). The cells were harvested at 24 h for luciferase activity and at 48 h for immunoblotting or RNA extraction.
Immunostaining and microscopy
Cells were seeded on glass coverslips, fixed, permeabilized, stained with antibodies, and mounted on slides as described previously [24] . In some cases, adhered, washed cells were labeled with 10 lM mepacrine for 5 min prior to three rapid phosphate-buffered saline rinses and immediate fixation [23] . Nuclear staining was performed with 30 nM 4 0 ,6-diamidino-2-phenylindole for 10 min at room temperature. The fluorophores used were fluorescein isothiocyanate and Cy3 (Jackson ImmunoResearch Laboratories). Cells were imaged on a Leica DM IRE2 microscope (Wetzlar, Germany) with a TCS SL confocal system, with a 9 63/1.40 numerical aperture (NA) oil immersion objective at room temperature and Leica imaging software, or on a Nikon E800 (Melville, NY, USA), with a 9 63/1.40 NA oilimmersion objective at room temperature and Q-CAPTURE software. Mepacrine fluorescence was visualized by use of the 488-nm filter cube or laser. Confocal images were captured by line sequential scanning with 4 9 line averaging and 3 9 frame averaging at a scan speed of 400 Hz. Post-acquisition image processing was performed with IM-AGEJ and ADOBE PHOTOSHOP. Operations included brightness/contrast adjustment to all pixels in the images and grouping of images. Pearson's correlation coefficients were calculated with Leica imaging software. Fluorescence intensity analysis was performed with IMAGEJ and Microsoft Excel. Corrected total cellular fluorescence was calculated as the average of individual cell fluorescence intensities divided by the single cell area, background subtracted, with > 100 cells per sample.
Web resources
Potential transcription factor RUNX1 binding sites were predicted by use of the TFsearch system (http://www.cb rc.jp/research/db/TFSEARCH.html).
Statistical analysis
Results are expressed as the mean AE standard error of the mean. Differences were compared by use of Student's ttest, and considered to be significant at P-values of < 0.05.
Results
Platelet pallidin expression and DG numbers are decreased in the patient
Expression profiling of platelets from the patient with RUNX1 haplodeficiency showed that PLDN expression was decreased as compared with platelets from normal subjects (fold change of 0.239, P = 0.029) [20] . This was validated by quantitative PCR: the level of platelet PLDN mRNA in the patient was lower than that in four healthy subjects (Fig. 1A) . Platelet transcript levels of the other members of the BLOC-1 complex were detected, and their levels were not decreased [20] . Immunofluorescence studies with anti-pallidin antibodies showed that the corrected total cellular immunofluorescence (CTCF) was reduced by~33% in patient platelets as compared with those from a control subject (Fig. 1B) , indicating decreased pallidin expression. We examined platelet levels of two other members of the BLOC-1 complex, i.e. cappuccino (BLOC1S4), and snapin, which were previously reported to be decreased in a patient with PLDN mutation (HPS-9) [22] , and these were not decreased in the patient (Fig. S1 ). The levels of dysbindin linked to HPS-7 [13] were also not decreased (not shown). Assessment of platelet DGs with anti-CD63 (granulophysin) antibody, which is a marker for DGs [25] , showed a decreased mean number of CD63-positive DGs per platelet in the patient as compared with the control subject (Fig. 1C) . The mean number of DGs in the control subject was consistent with previous reports [25] .
Studies on platelets from two additional patients with RUNX1 mutations also showed decreased PLDN mRNA and protein levels, as well as decreased numbers of DGs (Fig. 2) , as compared with healthy controls. (Fig. 3B) . In each case, PCR amplification showed enrichment by anti-RUNX1 antibodies, but not control IgG, of the regions encompassing the RUNX1 consensus sites, indicating RUNX1 binding in vivo to the PLDN promoter at several sites.
RUNX1 binds PLDN promoter sequences
EMSA studies with nuclear extracts from PMA-treated HEL cells showed RUNX1 binding to probes containing each of the six consensus sites (Fig. 4) . In studies with the probe containing site 1 (Fig. 4) , there was protein binding (Fig. 4 , Site 1, lane 2) that was competed for by excess unlabeled probe (lane 3), and supershifted by anti-RUNX1 antibodies (lane 4), but not by non-specific IgG (lane 5), indicating that RUNX1 was a component of the protein-DNA complex. Similarly, in studies with probes containing sites 2-6 (Fig. 4 , Sites 2-6), there was specific protein binding that was competed for by excess unlabeled probe, and one or more bands observed were supershifted in studies with probes bearing sites 2, 3, 5, and 6 (Fig. 4, Sites 2, 3 , 5, and 6). In studies with the probe with site 4 (Fig. 4, Site 4) , there was no supershift noted, but the protein binding was competed for by anti-RUNX1 antibodies, but not by non-specific IgG. This is consistent with RUNX1 binding to the probe. Together, these studies demonstrate that RUNX1 binds in the regions encompassing several of the RUNX1 consensus sites in the PLDN promoter.
RUNX1 binding sites have promoter activity
In luciferase reporter studies in HEL cells, mutation of consensus sites 1-4 and 6 in the PLDN promoter region resulted in a 60-70% reduction in PLDN promoter activity (Fig. 5) , indicating that these sites, excepting site 5, were functional. 
RUNX1 modulates PLDN expression and promoter activity
RUNX1 overexpression in HEL cells increased PLDN promoter activity, and pallidin and RUNX1 mRNA and protein levels (Fig. 6A) . The protein levels of RUNX1 and pallidin increased by a mean of 4.3-fold (P < 0.01) and 75% (P < 0.05), respectively (Fig. 6A ). RUNX1 downregulation with siRNA decreased PLDN promoter activity by~65%, and RUNX1 and PLDN at the mRNA and protein levels (Fig. 6B) . The protein levels of RUNX1 and pallidin were decreased by a mean of 54% (P < 0.005) and 29% (P < 0.05), respectively. PLDN downregulation decreased the pallidin protein level by 65%, but not that of RUNX1 (Fig. 6C) , indicating that pallidin knockdown does not affect RUNX1 levels. Moreover, there were no decreases in the levels of cappuccino or snapin protein (Fig. S2 ) or of dysbindin (not shown) on RUNX1 downregulation. Staining with anti-pallidin antibodies showed that the CTCF was reduced by 51.2% AE 11.1% in RUNX1 siRNA-transfected cells as compared with controls ( Fig. 6D) , confirming decreased pallidin protein expression in RUNX1-depleted cells.
RUNXI and PLDN downregulation impairs DG biogenesis
On the basis of the known roles of pallidin in DG/vesicle biogenesis, we considered the effects of RUNX1 and pallidin depletion on DG biogenesis. Previous studies have shown DG biogenesis in megakaryocytic MEG-01 cells [23] . To evaluate DG biogenesis in HEL cells, we induced megakaryocytic differentiation by treatment with PMA.
After 3 days of PMA exposure, most cells showed bilobed nuclei, which expanded to multilobed nuclei by 7 days of PMA exposure (Fig. S3) . We assessed DGs in PMA-treated HEL cells by using multiple markers. Mepacrine is incorporated by megakaryocytes and platelets into the DGs by uptake, and is a DG marker [23, 26] . PMA-treated HEL cells showed incorporation of mepacrine into large puncta, which were enriched in both CD63 and Rab7 -two markers for multivesicular bodies and late endosomes that also indicate maturing DGs [23, 27] . These findings are consistent with the formation of DGs in these differentiated HEL cells (Fig. 7A) . siRNA downregulation of RUNX1 or PLDN decreased mepacrine uptake, displaced CD63 from large puncta, and decreased Table S2 . Ab, antibody. colocalization of CD63 with mepacrine, indicating a reduction in DG numbers in these cells (Fig. 7B,C) . Rab7 enrichment in these large puncta was also lost on knockdown of RUNX1 or PLDN (Fig. S4 ). The findings with RUNX1 downregulation were similar to those with downregulation of PLDN, a member of the BLOC-1 complex that is implicated in DG biogenesis. Together, these findings with mepacrine, CD63 and Rab7 are consistent with dysregulated DG biogenesis caused by downregulation of RUNX1 or PLDN. Downregulation of either RUNX1 or PLDN did not alter CD63 protein levels as determined by immunoblotting (Fig. 7D ) or mRNA levels (not shown), indicating that CD63 is not a target of RUNX1, and consistent with the conclusion that loss of functional RUNX1 or pallidin leads to disrupted CD63 trafficking rather than a decrease in CD63 protein synthesis.
Discussion
PLDN downregulation provides a cogent mechanism for the DG deficiency associated with RUNX1 mutations. Our studies show that platelet pallidin expression was decreased in the patient with RUNX1 haplodeficiency, along with a decrease in DG numbers, as shown by use of the DG marker CD63 [25] (Fig. 1 ). This is corroborated by studies in two siblings of an unrelated family with RUNX1 mutations (Fig. 2) . Platelet DG deficiency has been reported in patients with RUNX1 mutations, and some patients with a DG deficiency have subsequently been shown to have a RUNX1 mutation [2, 5, 6, 11] . Pallidin deficiency resulting from homozygous mutation in PLDN is associated with platelet DG deficiency in the pallid mouse [21] and in human HPS-9 [22] . Pallidin is one of eight proteins constituting the BLOC-1 complex, which is involved in DG biogenesis [13] ; of these eight, only PLDN platelet transcript levels were significantly decreased in our patient [20] . At the protein level, we found that the levels of platelet cappuccino, snapin, (Fig. S1 ) and dysbindin, three other members of the BLOC-1 complex, were not decreased, suggesting that RUNX1 is not a master transcriptional regulator of all members of this complex. Our studies provide evidence that PLDN is a direct transcriptional target of RUNX1, and is regulated by RUNX1 in megakaryocytic cells. We provide evidence that RUNX1 binds to the PLDN promoter (Figs 3 and 4) , and the reporter gene expression studies demonstrate that the sites have promoter activity (Fig. 5) . Overexpression of RUNX1 increased pallidin expression and PLDN promoter activity (Fig. 6 ). RUNX1 downregulation elicited the opposite effects (Fig. 6) . These findings provide a mechanism for the decreased platelet PLDN mRNA expression in our patient.
Platelet DG numbers were decreased in the patient's platelets in studies using CD63 as a marker (Fig. 1C) . Our studies also suggest that CD63 is not a transcriptional target of RUNX1; platelet CD63 transcript levels were not decreased in the patient, and HEL cell CD63 protein levels were not decreased by RUNX1 or PLDN downregulation (Fig. 7D) . Thus, the downregulation of CD63 by RUNX1 haplodeficiency is not the cause of the DG defect. In HPS patients, cellular CD63 gene expression was also normal [28] .
In HEL cells, localization of the DG membrane protein CD63 was altered on RUNX1 downregulation (Fig. 7B,C) . Similar effects were observed with PLDN knockdown (Fig. 6B,C) , suggesting that CD63 mislocalization with RUNX1 knockdown reflected pallidin downregulation. Previous studies have shown that the BLOC-1 complex, which includes pallidin, is required for cargo-specific sorting from vacuolar early endosomes towards mature vesicles, which include DGs and melanosomes [29, 30] . Deficiency of BLOC-1 components as occurs in the HPS patients [22, 31, 32] or following knockdown in fibroblasts or melanocytes results in an altered distribution of the specific lysosome-related organelle cargo [29, 30] . Specifically, downregulation of pallidin has been shown to result in mislocalization of CD63 in fibroblasts and of tyrosinereceptor related protein 1 (a DG marker) in melanocytes [22, 29, 30] . Our findings on downregulation of RUNX1 or PLDN in HEL cells are similar (Fig. 7) , and recapitulate these reported findings. Moreover, the defects noted under these conditions in the retention of mepacrine (Fig. 7) , which is normally incorporated rapidly into DGs, indicate that RUNX1 regulates DG biogenesis in part through pallidin. The displacement of CD63 from DGs by RUNX1 or PLDN knockdown, which did not suppress CD63 expression (Fig. 7D) , suggests possible repurposing of cargo away from DGs and towards other pathways in RUNX1-depleted or pallidin-depleted cells [23] . The fate of CD63 needs to be established in future studies. Overall, the studies with two independent markers, i.e. CD63 and mepacrine, provide strong support for the concept that pallidin downregulation alters DG biogenesis and is a potential mechanism for DG deficiency in RUNX1 haplodeficiency. It is important to note that the patient reported with HPS-9 had a homozygous mutation in PLDN [22] , and it is unclear whether heterozygotes have a subtle granule abnormality in platelets or melanosomes. On the basis of the magnitude of the decrease in pallidin levels noted in our patients, we postulate that the DG deficiency results from a combined effect of decreased expression of PLDN and of other genes that are RUNX1 targets and involved in vesicle trafficking [20] . The latter would encompass genes such those encoding Rab proteins and other proteins implicated in vesicle transport, as well as yet unknown genes involved in DG biogenesis and regulated by RUNX1 [20] .
The DG defect alone does not account for all aspects of the platelet dysfunction noted in RUNX1 haplodeficiency. As previously shown by us [20] , several genes are downregulated in RUNX1 haplodeficiency, indicating that the underpinnings of the platelet dysfunction are complex, involving multiple pathways. Agonist-induced DG secretion is diminished in RUNX1 haplodeficiency [1, 3, 7, 14] , and may be associated with impaired secretion of a-granule contents and acid hydrolases [7] . The decreased DG secretion probably results from abnormalities in the DGs as such, as well as in mechanisms governing secretion, the latter being evidenced by documented abnormalities in processes governing exocytosis, including myosin and pleckstrin phosphorylation [14] . Similarly, downregulation of other genes related to vesicle transport [20] may also contribute to defective DG formation and function.
Overall, DG deficiency is one of the major platelet abnormalities reported in patients with RUNX1 mutations [2, 5, 6, 9] . Decreased expression of PLDN and associated aberrant DG formation constitutes a cogent mechanism for DG deficiency resulting from RUNX1 haplodeficiency. Our studies provide new insights into the role of pallidin in DG defects outside of HPS. The gene dysregulation associated with RUNXI haplodeficiency is a valuable model for obtaining novel insights into human platelet biology. Addendum G. F. Mao performed the research, analyzed and interpreted data, and contributed to the drafting of the paper.
L. E. Goldfinger designed and performed the research, analyzed and interpreted the data, and contributed to the drafting and review of the manuscript. M. P. Lambert characterized the platelet defects and the RUNX1 mutation in two of the patients studied. D. C. Fan and G. Jalagadugula performed the research. R. Freishtat performed the research and contributed to discussion of results. A. K. Rao conceived, designed and performed research, interpreted data, and wrote the paper. All authors have read and approved the manuscript. Table S1 . Oligonucleotide primer sequences used in PCR for ChiP analysis. Table S2 . Oligonucleotide probe sequencs used in EMSA for DNA and protein binding analysis. Table S3 . Oligonucleotide primers used in PCR amplification for PLDN promoter sequences. Table S4 . Oligonucleotide sequences used in quantitative real-time PCR.
